TP53 and non-small cell lung carcinoma: Here we present novel findings demonstrating the involvement of PLA2 in the S100A11-driven chemoresistance of NSCLC cells (both p53 wt and mutant), as the cPLA2 knock-down resulted in decreased apoptotic response to cisplatin and oxaliplatin, while PLA2 inhibitor abrogated chemosensitizing effect of S100A11 silencing upon treatment with these agents (Fig. 5).